Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11019544 | Drug Discovery Today | 2018 | 8 Pages |
Abstract
Next-generation sequencing (NGS) enabled high-throughput analysis of genotype-phenotype relationships on human populations, ushering in a new era of genetics-informed drug development. The year 2017 was remarkable, with the first FDA-approved gene therapy for cancer (Kymriahâ¢) and for inherited diseases (LUXTURNAâ¢), the first multiplex NGS panel for companion diagnostics (MSK-IMPACTâ¢) and the first drug targeting a genetic signature rather than a disease (Keytruda®). We envision that population-scale NGS with paired electronic health records (EHRs) will become a routine measure in the drug development process for the identification of novel drug targets, and that genetically stratified clinical trials could be widely adopted to improve power in precision-medicine-guided drug development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Abolfazl Doostparast Torshizi, Kai Wang,